title: Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-eluting versus zotarolimus-eluting stents: a meta-analysis.
abstract: BACKGROUND
  Compared with the zotarolimus-eluting stent (ZES), the everolimus-eluting stent (EES) has reduced the risk of stent restenosis and thrombosis as found in a number of randomized-controlled trials (RCTs). However, the benefits have been variable.
  
  
  METHODS
  We evaluate the long-term effect of EES and ZES on the risk of stent thrombosis and target lesion revascularization in patients receiving PCI. We identified RCTs by a systematic search of MEDLINE, EMBASE, and Cochrane Database.
  
  
  RESULTS
  Five RCTs (9853 patients) were included. Overall, EES significantly reduced the risk of target lesion revascularization [odds ratio (OR), 0.77; 95% confidence interval (CI), 0.62-0.95; P=0.01] compared with ZES therapy. However, there was no difference in the risk of target vessel revascularization (OR, 0.93; 95% CI, 0.78-1.10; P=0.38) and definite/probable stent thrombosis (OR, 0.83; 95% CI, 0.56-1.25; P=0.37) between the two groups. Furthermore, the risk of mortality (OR, 1.04; 95% CI, 0.84-1.27; P=0.73), myocardial infarction (OR, 0.95; 95% CI, 0.74-1.23; P=0.70), and major adverse cardiac event (OR, 0.96; 95% CI, 0.84-1.10; P=0.53) was similar between the two groups.
  
  
  CONCLUSIONS
  The new-generation Resolute-ZES and EES have a similar long-term safety and efficacy profile.
authors.affiliation: Department of Cardiology, Changzhou TCM Hospital, Changzhou, China.
authors.forename: Li
authors.initials: L
authors.lastname: Qi-Hua
authors.forename: Zhang
authors.initials: Z
authors.lastname: Qi
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yu
authors.forename: Li
authors.initials: L
authors.lastname: Xiao-Long
authors.forename: Ji
authors.initials: J
authors.lastname: Hai-Gang
authors.forename: Yin
authors.initials: Y
authors.lastname: Jian-Feng
authors.forename: Sun
authors.initials: S
authors.lastname: Yi
mesh_terms: D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D003328:Coronary Thrombosis / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage*; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D016017:Odds Ratio; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D011474:Prosthesis Design; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus